This report describes the public health response to a Purpureocillium lilacinum keratitis outbreak in New York City associated with an ophthalmology clinic.
This report describes the prevalence of physical and sexual violence perpetration by young men and associations of these events with their exposure to violence during childhood.
This report describes the public health response to a measles outbreak in Colorado among people exposed to an infectious traveler who arrived in Colorado in May 2025 on an international flight.
This report describes the prevalence of physical and sexual violence perpetration by young men and associations of these events with their exposure to violence during childhood.
This report describes CDC's multistate investigation to confirm the genetic relatedness of infections in an E. coli outbreak linked to walnuts and identify additional cases.
This report describes the public health response to three patients from different states who developed severe illness after self-injecting botulinum toxin.
This report describes a CDC collaboration with professional organizations and health departments to enroll birthing hospitals in the Vaccines for Children Program to increase infant immunization against respiratory syncytial virus.
This report describes a multicenter case-control investigation that found nirsevimab was 80% effective at preventing RSV-associated ICU admissions among infants.
This report describes two residents of a long-term care facility (both older than age 85) who developed Group G -hemolytic Streptococcus in a long-term care facility.
This report describes the severity of the 2024-25 flu season and flu-associated hospitalizations. The Morbidity and Mortality Weekly Report (MMWR) Series is prepared by the Centers for Disease Control and Prevention (CDC).
This report describes a case of highly pathogenic avian influenza A(H5N1) identified in a school-aged child in California with no known source of exposure.
This report describes an analysis of infants born from October 2023-March 2024 that had respiratory syncytial virus (RSV) immunization coverage through nirsevimab monoclonal antibodies or maternal vaccination.